
    
      The objective of this study is to evaluate the safety, efficacy and pharmacokinetics of
      sofosbuvir 400mg once daily plus ribavirin 1000-1200 mg daily in HIV-infected patients on
      fixed dose co-formulation emtricitabine/tenofovir/cobicistat/elvitegravir (Stribild).
    
  